TABLE 2.
Inhibitory activities of lipopeptide fusion inhibitors on divergent HIV-1 subtypesa
| Pseudovirus | Subtype | Mean IC50 ± SD (pM) for: |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| T-20 | LP-52 | LP-80 | LP-83 | LP-86 | LP-93 | LP-94 | LP-95 | C34-Chol | ||
| 92RW020 | A | 3,798 ± 190.48 | 38.54 ± 9.18 | 9.09 ± 0.91 | 4.52 ± 0.48 | 5.99 ± 1.9 | 15.18 ± 1.15 | 10.18 ± 2.41 | 187.29 ± 101.8 | 90.02 ± 8.72 |
| 92UG037.8 | A | 6,601.33 ± 572 | 26.53 ± 1.94 | 3.28 ± 0.62 | 4.14 ± 0.71 | 4.22 ± 1.49 | 25.62 ± 6.75 | 20.92 ± 0.54 | 54.25 ± 5.75 | 116.44 ± 20.51 |
| 398-F1_F6_20b | A | 21,653.33 ± 3,381.83 | 10.39 ± 1.4 | 1.54 ± 0.07 | 1.23 ± 0.23 | 1.37 ± 0.26 | 2.98 ± 0.04 | 1.26 ± 0.65 | 23.42 ± 1 | 14.97 ± 1.88 |
| PVO | B | 65,066.67 ± 5,256.24 | 33.01 ± 4.62 | 11.05 ± 2.72 | 3.61 ± 0.58 | 7.43 ± 2.5 | 20.29 ± 12.56 | 5.67 ± 2.06 | 101.98 ± 37.93 | 106.22 ± 11.67 |
| pREJO4541 | B | 53,141.67 ± 4,642.64 | 8.77 ± 1.21 | 1.15 ± 0.35 | 4.68 ± 0.26 | 4.74 ± 2.27 | 15.10 ± 3.03 | 8.79 ± 2.35 | 1,148.57 ± 271.92 | 66.52 ± 9.46 |
| SF162 | B | 15,646 ± 2,881.32 | 13.18 ± 0.41 | 4.15 ± 2.48 | 1.75 ± 0.5 | 2.14 ± 0.52 | 5.70 ± 0.53 | 3.05 ± 0.14 | 25.61 ± 2.97 | 32.41 ± 1.83 |
| JRFL | B | 9,887.33 ± 474.31 | 45.19 ± 4.78 | 9.31 ± 1.61 | 3.50 ± 0.55 | 4.67 ± 0.38 | 8.23 ± 0.95 | 4.3 ± 0.95 | 24.89 ± 0.73 | 115.2 ± 7.29 |
| SC422661.8 | B | 14,668.67 ± 1,976.15 | 6.64 ± 0.87 | 1.92 ± 0.89 | 3.29 ± 0.48 | 5.76 ± 1.71 | 12.47 ± 2.93 | 6.01 ± 0.12 | 1,203.33 ± 122.98 | 73.39 ± 9.22 |
| AC10.0.29 | B | 2,947.67 ± 585.03 | 8.50 ± 1.83 | 4.84 ± 0.81 | 1.95 ± 0.51 | 5.14 ± 0.76 | 8.98 ± 6.49 | 4.63 ± 2.93 | 17.81 ± 1.34 | 34.72 ± 4.76 |
| TRO.11b | B | 6,550.67 ± 902.82 | 18.49 ± 4.18 | 3.44 ± 0.68 | 1.35 ± 0.47 | 2.45 ± 0.11 | 6.1 ± 1.32 | 2.85 ± 1.17 | 66.65 ± 25.43 | 28.73 ± 2.03 |
| X2278_C2_B6b | B | 5,412.33 ± 275.16 | 7.64 ± 2.6 | 0.6 ± 0.46 | 1.76 ± 0.94 | 0.77 ± 0.06 | 3.24 ± 0.78 | 2.38 ± 0.08 | 36.17 ± 21.04 | 9.22 ± 2.32 |
| R3A | B | 7,497 ± 572.5 | 12.52 ± 3.35 | 5.67 ± 1.14 | 2.48 ± 0.47 | 4.31 ± 0.09 | 3.97 ± 0.52 | 6.83 ± 1.02 | 77.94 ± 17.99 | 42.79 ± 16.02 |
| B01 | B′ | 77,094.33 ± 1,690.12 | 12.1 ± 1.41 | 3.77 ± 0.41 | 3.87 ± 0.97 | 6.36 ± 1.72 | 7.31 ± 0.54 | 6.84 ± 2.82 | 200.37 ± 89.2 | 46.31 ± 7.22 |
| B02 | B′ | 12,801 ± 1,161.16 | 9.96 ± 1.08 | 8.22 ± 0.95 | 3.51 ± 0.23 | 6.14 ± 1.59 | 8.74 ± 1.61 | 6.45 ± 2.18 | 191.33 ± 24.13 | 61.34 ± 8.79 |
| B04 | B′ | 5,514 ± 388.23 | 7.86 ± 1.31 | 4.31 ± 1.54 | 2.79 ± 0.28 | 6.38 ± 0.32 | 3.66 ± 0.19 | 2.6 ± 0.08 | 397.1 ± 43.2 | 77.86 ± 10.18 |
| 43-22 | B′ | 16,565 ± 1,544.92 | 5.89 ± 1.07 | 2.18 ± 1.06 | 2.19 ± 1.24 | 3.54 ± 0.71 | 4.05 ± 1.6 | 4.81 ± 3.56 | 41.01 ± 21.5 | 25.76 ± 5.66 |
| Du156 | C | 15,732.67 ± 1,334.81 | 7.01 ± 2.14 | 2.04 ± 0.68 | 1.72 ± 0.37 | 2.30 ± 0.26 | 3.98 ± 0.54 | 2.71 ± 0.66 | 104.38 ± 5.31 | 26.95 ± 2.13 |
| ZM53M.PB12 | C | 23,173.33 ± 2,129.02 | 16.55 ± 3.86 | 7.27 ± 1.83 | 4.19 ± 0.78 | 4.59 ± 0.69 | 10.60 ± 0.93 | 7.13 ± 2.6 | 119.58 ± 83.57 | 83.42 ± 8.69 |
| CAP210.2.00.E8 | C | 163,602 ± 16,751.97 | 29.71 ± 6.17 | 10.47 ± 0.2 | 3.69 ± 0.1 | 6.55 ± 1.96 | 13.39 ± 7.23 | 7.75 ± 3.36 | 309.59 ± 160.39 | 77.8 ± 10.85 |
| CAP45.2.00.G3 | C | 111,593.33 ± 16,592.38 | 7.87 ± 2.35 | 3.02 ± 1.73 | 1.45 ± 0.51 | 1.24 ± 0.16 | 5.62 ± 3.41 | 2.62 ± 0.89 | 13.31 ± 2.76 | 10.95 ± 1.55 |
| CE703010217_B6b | C | 44,885.33 ± 1,800.47 | 11.92 ± 3.02 | 4.45 ± 1.8 | 1.70 ± 0.42 | 3.42 ± 0.3 | 10.16 ± 3.57 | 4.73 ± 0.69 | 36.52 ± 4.59 | 83.22 ± 10.65 |
| HIV_25710-2.43b | C | 13,219.67 ± 2,638.09 | 19.47 ± 2.7 | 3.40 ± 0.28 | 2.28 ± 0.44 | 3.34 ± 1.06 | 7.76 ± 1.74 | 6.12 ± 0.23 | 118.50 ± 51.16 | 47.28 ± 6.71 |
| CE1176_A3b | C | 8,452 ± 804.32 | 12.77 ± 5.33 | 2.25 ± 0.98 | 4.03 ± 0.67 | 5.13 ± 1.06 | 11.45 ± 2.3 | 9.66 ± 2.57 | 38.97 ± 2.86 | 82.73 ± 3.01 |
| X1632-S2-B10b | G | 17,464.33 ± 1,656.28 | 24.92 ± 1.01 | 3.90 ± 2.35 | 2.60 ± 0.44 | 5.67 ± 1.78 | 8.28 ± 1.66 | 7.21 ± 1.16 | 46.22 ± 19.01 | 92.06 ± 9.06 |
| 246_F3_C10_2b | A/C | 36,237 ± 1,246.91 | 14.28 ± 2.11 | 4.87 ± 2.34 | 1.68 ± 0.18 | 2.41 ± 0.35 | 3.76 ± 0.22 | 2.71 ± 0.41 | 12.34 ± 1.77 | 40.04 ± 2.91 |
| AE03 | A/E | 16,585.33 ± 2,284.25 | 13.26 ± 1.34 | 2.72 ± 1.29 | 1.80 ± 0.75 | 3.14 ± 0.13 | 3.30 ± 1.29 | 3.24 ± 1.99 | 180.97 ± 31.35 | 16.39 ± 4.91 |
| GX11.13 | A/E | 30,265.67 ± 2,927.55 | 8.93 ± 1.13 | 5.35 ± 0.7 | 3.80 ± 0.41 | 8.04 ± 2.14 | 11.59 ± 0.76 | 14.78 ± 2.28 | 52.58 ± 25.92 | 141.57 ± 20.12 |
| SHX335.24 | A/E | 37,818.33 ± 2,638.78 | 20.64 ± 3.82 | 5 ± 2.74 | 1.73 ± 0.62 | 2.44 ± 0.62 | 5.61 ± 0.43 | 2.16 ± 1.05 | 21.33 ± 2.62 | 47 ± 4.71 |
| CNE8b | A/E | 22,938± 2,408.89 | 9.57 ± 2.59 | 7.13 ± 4.21 | 5.06 ± 0.4 | 7.23 ± 1.48 | 12.57 ± 1.24 | 23.22 ± 8.15 | 108.34 ± 16.64 | 113.75 ± 5.16 |
| CNE55b | A/E | 27,066± 1,864.23 | 13.4 ± 4.37 | 1.48 ± 0.53 | 1.93 ± 0.7 | 5.28 ± 0.41 | 5.54 ± 2.39 | 3.27 ± 1.29 | 15.60 ± 4.86 | 39.37 ± 5.66 |
| CH64.20 | B/C | 33,537.33 ± 3,582.23 | 33.23 ± 1.79 | 8.86 ± 4.39 | 4.42 ± 2.71 | 4.07 ± 0.97 | 9.73 ± 7.28 | 5.49 ± 4.5 | 25.99 ± 5.11 | 42.62 ± 2.97 |
| CH070.1 | B/C | 205,182.67 ± 3,509.09 | 38.19 ± 3.78 | 12.34 ± 8.06 | 4.25 ± 0.6 | 13.38 ± 0.06 | 27.92 ± 5.84 | 11.55 ± 0.29 | 105.42 ± 17.88 | 212.54 ± 12.73 |
| CH110 | B/C | 32,772.67 ± 1,753.18 | 12.57 ± 1.37 | 3.3 ± 0.01 | 2.79 ± 0.86 | 4.65 ± 1.06 | 10.22 ± 3.84 | 5.87 ± 0.09 | 51.29 ± 28.55 | 41.08 ± 1.65 |
| CH119.10b | B/C | 43,322.67 ± 2,147.37 | 11.81 ± 2.8 | 4.05 ± 0.93 | 2.35 ± 0.35 | 1.95 ± 0.07 | 7.03 ± 1.1 | 5.19 ± 0.98 | 63.80 ± 8.8 | 41.04 ± 4.18 |
| CH120.6 | B/C | 14,702.33 ± 2,251.62 | 18.83 ± 1.9 | 7.96 ± 3.5 | 4.53 ± 1.36 | 14.42 ± 1.28 | 26 ± 5.13 | 17.34 ± 0.26 | 67.34 ± 24.52 | 101.34 ± 8.58 |
| BJOX002000.03.2b | B/C | 27,124.33 ± 4,319.36 | 33.28 ± 4.21 | 5.51 ± 2.53 | 2.14 ± 0.73 | 6.02 ± 0.25 | 9.9 ± 1.41 | 5.12 ± 0.6 | 70.04 ± 29.5 | 67.89 ± 5.65 |
| Mean | 34,736.67 | 17.32 | 5 | 2.91 | 4.91 | 9.89 | 6.54 | 148.88 | 65.3 | |
a
The assay was performed in triplicates and repeated three times.
b
The global panel of HIV-1 Envs.